Violich Capital Management Inc. Purchases 2,611 Shares of Becton, Dickinson and Company $BDX

Violich Capital Management Inc. boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 15.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 19,825 shares of the medical instruments supplier’s stock after acquiring an additional 2,611 shares during the period. Violich Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $3,711,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. SOA Wealth Advisors LLC. lifted its stake in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 95 shares in the last quarter. Bell Investment Advisors Inc raised its holdings in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 128 shares during the period. Bank of Jackson Hole Trust lifted its position in shares of Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 95 shares in the last quarter. CVA Family Office LLC boosted its holdings in shares of Becton, Dickinson and Company by 79.5% in the second quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock worth $38,000 after acquiring an additional 97 shares during the period. Finally, CoreFirst Bank & Trust purchased a new position in shares of Becton, Dickinson and Company in the second quarter valued at $38,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX stock opened at $207.16 on Monday. The firm has a 50 day simple moving average of $195.88 and a two-hundred day simple moving average of $189.48. The stock has a market cap of $59.02 billion, a PE ratio of 35.53, a P/E/G ratio of 2.29 and a beta of 0.23. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.92 by $0.04. The company had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same period in the previous year, the business earned $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Monday, December 8th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date was Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Analyst Ratings Changes

A number of brokerages recently issued reports on BDX. Jefferies Financial Group increased their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler cut their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Bank of America upped their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Finally, Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Four equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $207.64.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 2,662 shares of company stock valued at $535,246 over the last three months. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.